SecBot SecBot
Biotech Drug Report Generated Sep 13, 2026

DARE-HPV

DARE·Dare Bioscience, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2 (IND cleared, trial not yet initiated)
Time to market
Unknown, Phase 2 trial has not yet initiated. If successful, a registrational Phase 3 trial and FDA review would follow, likely putting potential approval several years out (2029+).
Why 3/10
DARE-HPV has no hard dated binary catalyst in the next ~12 months, the Phase 2 trial has not yet initiated enrollment, and there is no PDUFA date or pivotal readout scheduled. The stock's value is dominated by the company's financial survival (cash runway, Nasdaq delisting risk, dilution overhang from the effective S-1 and recent warrant-heavy offering), not by this early-stage program. ImpactScore is 3: a pre-clinical-to-Phase 2 program at a financially distressed micro-cap with no imminent binary catalyst.
Actionable Insight NEUTRAL

DARE-HPV has no hard binary catalyst in the next ~12 months, the Phase 2 trial has not yet initiated enrollment. The stock's primary near-term driver is the company's survival (cash runway, Nasdaq compliance, dilution from the effective S-1), not DARE-HPV data. Watch for Phase 2 trial initiation press releases or partnership/licensing deals as potential catalysts, but the financial overhang dominates the risk/reward.

Price Chart

Loading chart...

Executive Summary

DARE-HPV is a preclinical-to-Phase 2 candidate from Daré Bioscience (DARE), a micro-cap women's health biotech. The FDA cleared its IND in February 2026, allowing a planned Phase 2 trial for persistent high-risk HPV infection, a condition with no FDA-approved therapy. The program benefits from non-dilutive ARPA-H funding (~$10M). However, the company is in severe financial distress (cash down to ~$12.6M, negative working capital, Nasdaq delisting risk, recent distressed equity offering), and DARE-HPV is an early-stage program with no clinical data yet. The stock trades near its 52-week low (~$0.70) with a ~$14M market cap, and analysts see massive implied upside (~1033% to $8.33 mean PT), but the company may not survive long enough to generate Phase 2 data without additional dilutive financing.

How It Works

DARE-HPV is an investigational therapeutic intended to treat persistent high-risk human papillomavirus (HPV) infection in women. The exact mechanism of action has not been publicly detailed by the company, but it targets a condition where the body fails to clear high-risk HPV strains that can lead to cervical cancer. Currently, there is no FDA-approved drug treatment for persistent high-risk HPV infection, the standard of care is watchful waiting or surgical intervention for precancerous lesions.

Trial Status

The FDA cleared Daré Bioscience's Investigational New Drug (IND) application for DARE-HPV in February 2026, enabling the company to proceed with a planned Phase 2 clinical trial. As of the most recent corporate updates, the Phase 2 trial had not yet begun enrolling patients. The program is supported by a non-dilutive ARPA-H contract worth approximately $10M, of which $9M had been received as of Q1 2026.

The Two-Sided Case

▲ Bull Case4
Persistent high-risk HPV infection has no FDA-approved drug therapy, DARE-HPV addresses a large unmet need in women's health and could be first-in-class if successful.
The program is supported by ~$10M in non-dilutive ARPA-H funding, reducing the cash burden on the company.
Multiple institutional investors (Vanguard, BlackRock, State Street, Northern Trust) added or doubled their DARE positions in Q2 2026, signaling institutional interest.
Analyst consensus is overwhelmingly bullish: 8 Buy/Strong Buy vs 1 Hold, with a mean price target of $8.33 (vs ~$0.70 current price), implying ~1033% upside.
▼ Bear Case6
The company is in severe financial distress: cash dropped from $24.7M to $12.6M in H1 2026, with negative working capital and an active Nasdaq delisting risk.
A distressed ~$6M public offering in August 2026 at $1.37/share included massive warrant coverage (up to 200% of shares), creating severe dilution overhang. An S-1 registration became effective in September 2026, enabling further dilution.
DARE-HPV is at the earliest clinical stage (Phase 2 not yet initiated), no safety or efficacy data exist yet. The drug could fail to demonstrate any benefit.
The stock trades near its 52-week low of $0.69, and the company may not have sufficient cash runway to complete the Phase 2 trial without additional dilutive financing.
Insider transactions show only RSU grants (compensation), no open-market insider purchases, suggesting management is not putting personal capital at risk.
The competitive landscape includes other HPV therapeutics in development (e.g., INO-3107 from Inovio, PDS0101 from PDS Biotechnology, ABI-2280 from Antiva Biosciences).

Upcoming Catalysts

  • Phase 2 trial initiation announcement
  • Phase 2 enrollment updates
  • Potential partnership or licensing deal for DARE-HPV
  • Company cash runway / financing events (going concern risk)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Dare Bioscience, Inc. 8-K DARE ·Originating report

Sources · 4

Hover a chip for the title
1 sec.gov2 globenewswire.com3 globenewswire.com4 globenewswire.com